NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- anti-PTK7/Auristatin-0101 antibody-drug conjugate PF-06647020
An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, anti-PTK7/Auristatin-0101 ADC PF-06647020 targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.
Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: ADC PF-06647020
anti-inactive tyrosine-protein kinase 7-ADC PF-06647020
anti-PTK7/vc-0101 ADC PF-06647020
Code name: h6M24-vc0101